In a world plagued by misinformation, a recent claim by the Children’s Health Defense (CHD) raises eyebrows and demands scrutiny. On November 7, 2023, CHD, an organization known for its anti-vaccination stance, led by Robert F. Kennedy, Jr., a 2024 U.S. presidential candidate, made an absurd assertion.
They claimed that a global initiative to vaccinate against human papillomavirus (HPV) in low- and middle-income countries could lead to a catastrophic "mass casualty event." This absurd prediction is allegedly due to the serious side effects of the vaccine, including autoimmune and neurological disorders.
These claims, however, are not grounded in scientific evidence. HPV, the most common sexually transmitted infection, is responsible for several types of cancers, including cervical cancer.
The HPV vaccine, approved globally in various forms such as Gardasil and Ceravix, has shown tremendous efficacy in preventing these cancers. Contrary to CHD's alarming assertion, studies in renowned medical journals have confirmed the vaccine's effectiveness in reducing the risk of cervical cancer.
Regarding the safety of the HPV vaccine, it's crucial to consider the role of the Vaccine Adverse Event Reporting System (VAERS). Established in 1990, VAERS is a platform for monitoring health concerns post-vaccination. While VAERS data is valuable, it is also susceptible to misuse.
Reporting an adverse event to VAERS does not imply causation. One claim is that HPV vaccination has a 6.5% rate of severe adverse event rate, based on VAERS data. This figure, sourced from a 2009 study, cannot establish a causal link between the vaccine and adverse events without a more thorough investigation into said rates in the non-vaccinated population (control group).
To further illustrate, autoimmune diseases and neurological disorders were present in the population even prior to the introduction of the HPV vaccine. Consequently, when evaluating whether the vaccine causes these conditions, a crucial factor is to compare the frequency of these adverse events after vaccination to their normal occurrence rate in the general population.
But multiple studies, including those conducted in the UK, Australia, and Scandinavia, have found no increased risk of conditions like Guillain-Barré syndrome, POTS, or chronic fatigue syndrome following HPV vaccination. In fact, these conditions existed in the population before the introduction of the vaccine, and their occurrence post-vaccination does not exceed the baseline rate.
The credibility of sources cited by CHD also comes into question. Publications used to support their claims have connections to the organization, raising concerns about potential conflicts of interest and biased reporting.
Overall, cervical cancer remains a significant global health issue. The evidence overwhelmingly supports the safety and efficacy of HPV vaccines in reducing the incidence of cervical cancer. As with any medical intervention, vaccines are not devoid of risks, but their benefits outweigh the potential adverse events.